<DOC>
	<DOCNO>NCT00568815</DOCNO>
	<brief_summary>The purpose study evaluate efficacy toxicity Rituximab combine ESHAP ( etoposide , methylprednisolone , cytarabine , cisplatin ) patient diffuse large B cell lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>Rituximab Combined With ESHAP Patients With Relapse Refractory Diffuse Large B Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description>The salvage therapy patient DLBCL still controversial . The investigator conduct study evaluate efficacy tolerability Rituximab combine ESHAP patient DLBCL . The patient enrol define relapsed refractory first-line chemotherapy like CHOP CHOP-like regimen .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age range 1870 year old Histological confirm diffuse large B cell lymphoma ECOG performance status 2 Life expectancy 3 month Relapse refractory firstline chemotherapy DLBCL No evidence bone marrow involvement Normal laboratory value : hemoglobin &gt; 8.0g/dl , neutrophil &gt; 1.5×109/L , platelet &gt; 80×109/L , serum creatine &lt; 1× upper limitation normal ( ULN ) , serum bilirubin &lt; 1× ULN , ALT AST &lt; 1.5× ULN Pregnant lactate woman Serious uncontrolled disease intercurrent infection The evidence CNS metastasis bone marrow involvement History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix History allergic reaction/hypersensitivity rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>Rituximab</keyword>
	<keyword>ESHAP</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Toxicity</keyword>
</DOC>